A Study Evaluating the Safety and Efficacy of the BD211 Drug Product in β-Thalassemia Major Participants

Hematologic Diseases Clinical Trial

Official title:

A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+Stem Cells Transduced With a Lentiviral Vector Encoding βA-T87Q-Globin

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05015920
• Other study ID #: 920IEC/AF/61/2019-01.0
• Status: Recruiting
• Phase: N/A
• Start date: July 10, 2021
• Est. completion date: February 23, 2025

Study information

• Verified date: October 2023
• Source: Shanghai BDgene Co., Ltd.
• Contact: Sanbin Wang, Dr.
• Phone: +86-871-2637866
• Email: sanbin1011[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1,open label,safety,and efficacy study in subjects with non-β0/β0 TDT β-thalassemia Major by transplanting BD211 drug product which is for autologous use only,via a single IV administration.

Description:

After collection of mobilised peripheral blood samples, the patient's autologous cells,enriched for CD34+ HSCs, undergo ex vivo transduction with lentiviral vector encoding βA-T87Q-globin to BD211 finished product,which is then infused intravenously into the patient after myeloablative busulfan conditioning to prepare bone marrow "niches" for engraftment of the HSCs. After discharge, subjects will be followed monthly, at a minimum, for 6 months and thereafter every 3 months for the remainder of the 24 months post-transplant. Evaluation will include Routine and special biological testing at regular intervals, collection of AEs and concomitant medications, and evaluation of disease specific biological and clinical parameters. Subjects will then be enrolled in a long-term follow-up protocol with annual evaluations for an additional 13 years post-transplant. The long-term follow-up study will focus on long-term safety, with an emphasis on integration site analysis, and long-term efficacy. This study will end when the last subject completes the Month 24 visit or discontinues from the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: February 23, 2025
• Est. primary completion date: February 23, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 35 Years

Eligibility

Inclusion Criteria:

1.5 to 35 years of age. 2.Be eligible for allogeneic HSCT based on institutional medical guideline, but without a matched related donor. 3.Transfusion-dependent ß-Thalassemia Major, regardless of the genotype, with the diagnosis confirmed by Hb studies. Subjects must be stable and maintained on an appropriate iron chelation regimen. Transfusion dependence is defined as requiring at least 100 mL/kg/year of packed red blood cells(pRBCs). 4.Have been treated and followed for at least the past 2 years in a specialized center that maintained detailed medical records, including transfusion history. 5.Be willing and able, in the Investigator's opinion, to comply with the study procedures outlined in the study protocol. If a pediatric subject, the subject's parent/legal guardian also must be willing and able to comply with the study procedures outlined in the study protocol.

Exclusion Criteria:

1. Availability of a willing matched HLA-identical sibling hematopoietic cell donor.

2. Positive for presence of human immunodeficiency virus, human T-lymphotropic virus, vesicular stomatitis virus G antibody.

3. Clinically significant, active bacterial, viral, fungal, or parasitic infection.

4. A white blood cell (WBC) count<3x109/L and/or platelet count<120x109/L

5. Receipt of an allogeneic transplant.

6. Receipt of erythropoietin within 3 months before HSCT harvest.

7. Contraindication to anesthesia for bone marrow harvesting.

8. Any of prior or current malignancy, myeloproliferative or immunodeficiency disorder.

9. Active relapsing malaria

10. Immediate family member with a known or suspected Familial Cancer Syndrome.

11. Diagnosis of significant psychiatric disorder of the subject that could seriously impede the ability to participate in the study.

12. Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile subjects.

13. Any other condition that would render the subject ineligible for HSCT, as determined by the attending transplant physician.

14. History of major organ damage.including Liver, Heart, Kidney disease, pulmonary hypertension ,severe iron overload, which in the opinion of the physician is grounds for exclusion.

15. Participation in another clinical study with an investigational drug within 30 days of screening.

16. Hydroxyurea therapy within 3 months before hematopoietic stem cell collection.

17. An assessment by the Investigator that the subject or parents of the subject will not comply with the study procedures outlined in the study protocol.

18. Subjects who have the desire to become a parent within the 27-month study period.

19. Prior receipt of gene therapy.

Related Conditions & MeSH terms

• beta-Thalassemia
• Hematologic Diseases
• Thalassemia

Intervention

Genetic:
• BD211 Drug Product
Transplantation of Autologous CD34+Stem Cells Transduced to BD211 finished Product with a Lentiviral Vector coding ßA-T87Q-Globin.

Locations

Country	Name	City	State
China	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China	Kunming	Yunnan

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai BDgene Co., Ltd.	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate the success and kinetics of HSC engraftment.	Three consecutive absolute neutrophil counts=500 cells/uL, three consecutive platelet values =20 e9/L, measure blood samples monthly after BD211 drug product infusion.	At multiple timepoints after infusion for 24 months.
Primary	Incidence of transplant-related mortality through 100 days post-transplant.		Up to 100 days post-HSCT.
Primary	Overall survival of maintenance phase.		Up to 24 months post-HSCT.
Primary	Post-transplant blood samples for replication competent lentivirus (RCL) testing.	The testing of any subject positivity will be considered an SAE and suspend the inclusion of new subjects.	At multiple timepoints after infusion for 24 months.
Primary	Assessment of Clonal dominance or leukemia/lymphoma and other malignancies.	Using peripheral blood of subjects for integration site analysis via LAM-PCR & deep sequencing.	At multiple timepoints after infusion for 24 months.
Primary	Incidence of treatment- related adverse events.	According to the requirements of the National Cancer Institute Common Terminology Standards for Adverse Events (NCI CTCAE) version 5.0, monitor laboratory parameters and the frequency and severity of clinical AEs.	Up to 24 months after BD211 drug product infusion.
Secondary	Quantify gene transfer efficiency and expression of BD211 drug product.	Expression of ßA-T87Q-globin chain in whole blood by assessing the ratio of ßA-T87Q-globin to a-globin, as well as ßA-T87Q-globin fractions in all ß-chains over time by HPLC.	Up to 24 months after engraftment.
Secondary	Quantify the hematopoietic chimerism resulting from treatment with BD211 drug product.	Measuring lentiviral vector copy number per diploid genome(c/dg) for evaluation.	Up to 24 months after engraftment.
Secondary	Measure the effects of transplantation with BD211 on the expression of disease-specific biological parameters and clinical events, including amounts of HbAT87Q in peripheral blood in grams per deciliter (g/dL).		Up to 24 months after engraftment.
Secondary	Reduction from baseline of RBC transfusion requirements (mL/kg) per month and year post-transplant.		Up to 24 months after engraftment.
Secondary	Duration of transfusion independence (months).		Up to 24 months after engraftment.
Secondary	Weighted average Hemoglobin during transfusion independence in grams per deciliter (g/dL).		Up to 24 months after engraftment.
Secondary	Changes from baseline in iron burden by assessing liver iron content (mg Fe/g dry weight).		Up to 24 months after engraftment.
Secondary	Changes from baseline in iron burden by assessing cardiac iron content using magnetic resonance imaging (MRI) T2* value (milliseconds, ms).		Up to 24 months after engraftment.